Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors (PEG)

Inclusion Criteria:

• Pathologic (histologic or cytologic) confirmation of metastatic or locally advanced solid tumor.
• Patients who have experienced disease progression after receiving appropriate standard / approved chemotherapy and for whom no further standard or palliative treatment measures exist, or who have chosen to decline standard or palliative treatment.
• One or more tumors measurable by RECIST criteria.
• Karnofsky performance status ≥ 70%.
• Recovery from any toxic or other effects of all previous therapy, including radiation, chemotherapy and surgery.
• Negative serum or urine pregnancy test result in women of childbearing potential.
• For men and women of child-producing potential, agreement to use effective contraception (hormonal or barrier birth control or abstinence) from the time of screening before study entry and throughout study participation.

Exclusion Criteria:

• Brain metastasis.
• New York Heart Association Class III or IV cardiac disease, myocardial infarction, or cardiac arrhythmia requiring medical therapy.
• Known allergy to hyaluronidase.
• Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions including psychiatric illness) that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
• Women currently breast feeding.
• Concurrent participation in any other interventional therapeutic study.